Our Mission: To discover, develop and deliver paradigm changing cancer detection technologies to enable early and more targeted intervention that cures previously deadly cancers.
Our approach has the potential to be the new gold standard for the detection of specific blood-borne markers generated by the body in response to cancers. Viomics is a molecular diagnostics company that uses innovative scientific, engineering, and business strategies to discover, develop and deliver paradigm changing cancer detection applications to enable early intervention that cures previously deadly cancers. We have developed and filed patents on the technology behind our first product, LungVantage™ , which is the most accurate and least expensive screen for non-small cell lung cancer (NSCLC) today.
We are a dedicated group passionate about translating discoveries to positively impact patient care. In addition to our work at Viomics, we also partner with the International Genomics Consortium and Paradigm Diagnostics, where we leverage decades of developing and commercializing many of the leading diagnostics in oncology today.